S&P 500   3,305.94 (-0.48%)
DOW   29,003.95 (-0.62%)
QQQ   222.91 (-0.43%)
AAPL   316.73 (-0.31%)
FB   220.27 (-0.47%)
MSFT   166.08 (+0.23%)
AMZN   1,878.61 (-0.47%)
CGC   23.90 (-0.91%)
NVDA   249.02 (-0.41%)
BABA   218.52 (-1.73%)
MU   59.71 (+0.91%)
GE   11.75 (+3.34%)
TSLA   558.09 (-2.01%)
AMD   50.93 (-0.97%)
T   38.76 (-0.72%)
ACB   1.99 (-2.45%)
F   8.96 (-2.29%)
NFLX   329.16 (+0.97%)
PRI   124.87 (-1.41%)
BAC   33.83 (-1.54%)
DIS   141.75 (-1.57%)
GILD   62.96 (-0.76%)
S&P 500   3,305.94 (-0.48%)
DOW   29,003.95 (-0.62%)
QQQ   222.91 (-0.43%)
AAPL   316.73 (-0.31%)
FB   220.27 (-0.47%)
MSFT   166.08 (+0.23%)
AMZN   1,878.61 (-0.47%)
CGC   23.90 (-0.91%)
NVDA   249.02 (-0.41%)
BABA   218.52 (-1.73%)
MU   59.71 (+0.91%)
GE   11.75 (+3.34%)
TSLA   558.09 (-2.01%)
AMD   50.93 (-0.97%)
T   38.76 (-0.72%)
ACB   1.99 (-2.45%)
F   8.96 (-2.29%)
NFLX   329.16 (+0.97%)
PRI   124.87 (-1.41%)
BAC   33.83 (-1.54%)
DIS   141.75 (-1.57%)
GILD   62.96 (-0.76%)
S&P 500   3,305.94 (-0.48%)
DOW   29,003.95 (-0.62%)
QQQ   222.91 (-0.43%)
AAPL   316.73 (-0.31%)
FB   220.27 (-0.47%)
MSFT   166.08 (+0.23%)
AMZN   1,878.61 (-0.47%)
CGC   23.90 (-0.91%)
NVDA   249.02 (-0.41%)
BABA   218.52 (-1.73%)
MU   59.71 (+0.91%)
GE   11.75 (+3.34%)
TSLA   558.09 (-2.01%)
AMD   50.93 (-0.97%)
T   38.76 (-0.72%)
ACB   1.99 (-2.45%)
F   8.96 (-2.29%)
NFLX   329.16 (+0.97%)
PRI   124.87 (-1.41%)
BAC   33.83 (-1.54%)
DIS   141.75 (-1.57%)
GILD   62.96 (-0.76%)
S&P 500   3,305.94 (-0.48%)
DOW   29,003.95 (-0.62%)
QQQ   222.91 (-0.43%)
AAPL   316.73 (-0.31%)
FB   220.27 (-0.47%)
MSFT   166.08 (+0.23%)
AMZN   1,878.61 (-0.47%)
CGC   23.90 (-0.91%)
NVDA   249.02 (-0.41%)
BABA   218.52 (-1.73%)
MU   59.71 (+0.91%)
GE   11.75 (+3.34%)
TSLA   558.09 (-2.01%)
AMD   50.93 (-0.97%)
T   38.76 (-0.72%)
ACB   1.99 (-2.45%)
F   8.96 (-2.29%)
NFLX   329.16 (+0.97%)
PRI   124.87 (-1.41%)
BAC   33.83 (-1.54%)
DIS   141.75 (-1.57%)
GILD   62.96 (-0.76%)
Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:TGTX - TG Therapeutics Stock Price, Forecast & News

$13.24
-0.23 (-1.71 %)
(As of 01/23/2020 09:48 AM ET)
Today's Range
$12.95
Now: $13.24
$13.45
50-Day Range
$7.12
MA: $11.06
$14.10
52-Week Range
$3.87
Now: $13.24
$14.89
Volume228,344 shs
Average Volume1.97 million shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.6
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$0.29 per share

Profitability

Net Income$-173,480,000.00
Net Margins-123,130.93%

Miscellaneous

Employees105
Market Cap$1.32 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableOptionable

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.


TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.33. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%. View TG Therapeutics' Earnings History.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for TG Therapeutics.

What price target have analysts set for TGTX?

4 analysts have issued 1 year price targets for TG Therapeutics' shares. Their forecasts range from $8.00 to $24.00. On average, they expect TG Therapeutics' share price to reach $15.25 in the next year. This suggests a possible upside of 13.2% from the stock's current price. View Analyst Price Targets for TG Therapeutics.

What is the consensus analysts' recommendation for TG Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:
  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (1/18/2020)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $17 PT. On the 1Q call, TG discussed recent pipeline progress, including the interim data for umbralisib in marginal zone lymphoma (MZL) that were presented at AACR last month and potential updates over the rest of 2019 and early 2020. After positive interim data for umbralisib in MZL, another major milestone will be discussing recent positive MZL data with the FDA. The final MZL data are to be presented toward the end of 2019 (we think potentially at the meantime, the company plans to present an update at ASCO and meet with the FDA to discuss accelerated approval." (5/13/2019)
  • 3. HC Wainwright analysts commented, "Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 35% POS for umbralisib in 40% POS for ublituximab in MS." (4/12/2019)

Has TG Therapeutics been receiving favorable news coverage?

News headlines about TGTX stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. TG Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for TG Therapeutics.

Are investors shorting TG Therapeutics?

TG Therapeutics saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 12,750,000 shares, a decline of 6.0% from the November 28th total of 13,570,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is presently 7.2 days. Approximately 14.8% of the shares of the company are sold short. View TG Therapeutics' Current Options Chain.

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $13.47.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $1.34 billion and generates $150,000.00 in revenue each year. TG Therapeutics employs 105 workers across the globe.View Additional Information About TG Therapeutics.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is http://www.tgtherapeutics.com/.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  547 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  835
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel